Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Palinologia de espécies de Asteraceae de utilidade medicinal para a comunidade da Vila Dois Rios, Ilha Grande, Angra dos Reis, RJ, Brasil Pollen morpology of species of Asteraceae with medicinal utility for the community from Vila Dois Rios, Ilha Grande, Angra dos Reis, Rio de Janeiro State, Brazil

O trabalho trata da morfologia polínica e de descrições taxonômicas de 12 espécies de Asteraceae correspondentes em 12 diferentes gêneros, distribuídos em nove tribos. Todas as espécies estudadas são utilizadas como medicamentos pelos moradores da Vila Dois Rios, Ilha Grande, Angra dos Reis, Rio de Janeiro. Neste estudo objetivou-se caracterizar os tipos polínicos das espécies usadas por esta comunidade e fornecer chaves diagnósticas de caracteres macromorfológicos e micromorfológicos que auxiliem a identificação das mesmas. A identificação taxonômica e palinológica correta é pré-requisito para estudos que validem a eficácia e segurança terapêutica dessas espécies. Deve-se considerar, ainda, que a utilização desses conhecimentos é importante para a comunidade, como por exemplo, na melissopalinologia. Os grãos de pólen foram acetolisados, medidos, descritos e ilustrados sob microscopia de luz. Para observar detalhes da superfície e abertura, grãos de pólen não acetolisados foram analisados em microscópio eletrônico de varredura. Foram estudadas as características dos grãos de pólen como forma, tamanho, constituição da sexina e abertura. Os resultados mostraram que a morfologia polínica é bem definida entre as espécies estudadas, podendo ser usada para sua identificação e sustenta o caráter euripalinológico de Asteraceae.<br>This study is a palynologycal characterization and taxonomic description of 12 species within 12 genera, distributed in nine tribes from Asteracaeae. All studied species are used as medicines by people from Vila Dois Rios and they occur in Ilha Grande. This work aimed to characterize the pollen grains of medicinal species of Asteraceae from Vila Dois Rios and provide diagnostic keys based on macromorphological and pollen characters to help their identification, since the correct taxonomic and palynological recognition of these species is necessary for further studies on therapeutic effectiveness and safety. It must be considered that these acknowledgments have economic importance for the community, as melissopalynology practices are taking place in Vila Dois Rios. The pollen grains were acetolysed, measured decribed and illustrated under light microscope. To observe details of aperture and surface, non acetolysed pollen grains were analysed under scanning electronic microscopy. Characteristics like shape, size, sexine and aperture constitution were studied. The results show that the palynological characterization of these species is a valuable tool to differ them from each other and sustains that Asteraceae is euripolinic